- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00535119
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the recommended dose for phase II studies of veliparib (ABT-888 ) that can be administered in combination with carboplatin and paclitaxel in patients with advanced solid malignancies. (Stratum I) II. To determine the recommended dose for phase II studies of veliparib that can be administered in combination with carboplatin and paclitaxel in patients with advanced solid malignancies that harbor a germline BRCA1/2 mutation. (Stratum II) (added 04/07/09)
SECONDARY OBJECTIVES:
I. To define the dose-limiting toxicity and other toxicities associated with the use of this combination.
II. To obtain preliminary evidence of antitumor activity in patients treated with this combination.
III. To evaluate the pharmacokinetic parameters of veliparib, carboplatin, and paclitaxel when administered as a combination.
IV. To conduct correlative science studies.
OUTLINE: This is a multicenter, dose-escalation study of veliparib. Patients are stratified according to BRCA status (no [stratum I] vs yes [stratum II]).
Patients receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib orally (PO) twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo peripheral blood mononuclear cell collection periodically for pharmacokinetic and biomarker studies.
After completion of study treatment, patients are followed up for 4 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University/Winship Cancer Institute
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid malignancy
- Patients enrolled in stratum II of the study must have BRCA1/2 mutation (added 04/07/09)
- Patients with CNS metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for > 3 months and must be off steroid treatment prior to study enrollment
- ECOG performance status 0-2
- Life expectancy > 12 weeks
- ANC ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- More than 3 weeks since prior radiotherapy
- Prior veliparib allowed
Exclusion Criteria:
- Known history of allergic reactions to veliparib, carboplatin, or Cremophor-paclitaxel
Uncontrolled intercurrent illness, including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness or social situations that would preclude compliance with study requirements
- Peripheral neuropathy > grade 1
- Inability to take oral medications on a continuous basis
- Active seizure or history of seizure disorder
- Evidence of bleeding diathesis
Received > 3 prior chemotherapy regimens for advanced stage disease for patients enrolled in stratum I (there is no upper limit on the number of prior regimens for patients enrolled in stratum II) (added 04/07/09)
- Adjuvant chemotherapy administered ≥ 2 years prior to enrollment to the study does not count as a prior chemotherapy regimen
- Other concurrent investigational agents
- Concurrent combination antiretroviral therapy for HIV-positive patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (enzyme inhibitor therapy and chemotherapy)
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined.
Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Correlative studies
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase II dose (RP2D) for each stratum
Time Frame: Up to 4 weeks
|
The RP2D for each cohort will be defined by the study separately.
Standard up & down dose-escalation scheme to determine the RP2D will be use, and toxicities will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
|
Up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: During course 1
|
Toxicities should be attributable to the study drug(s) to constitute DLT.
Patients will be considered evaluable for DLT if they are eligible, and if they receive any amount of treatment and experience DLT or complete the first course of treatment
|
During course 1
|
Frequency of platinum-DNA adducts
Time Frame: At baseline and 4 weeks post-treatment
|
Changes will be summarized as means and standard deviations.
A statistical test of the null hypothesis of no change in each variable will be done using the Wilcoxon signed-ranks procedure.
Measurements of the two variables at additional time points will be analyzed in a descriptive fashion using tables and plots.
|
At baseline and 4 weeks post-treatment
|
Incidence of stable disease (SD)
Time Frame: Measured from the start of the treatment until the criteria for progression are met, assessed up to 4 weeks post-treatment
|
SD is defined as neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter (LD) since the treatment started.
|
Measured from the start of the treatment until the criteria for progression are met, assessed up to 4 weeks post-treatment
|
PAR levels
Time Frame: Up to 4 weeks post-treatment
|
Changes will be summarized as means and standard deviations.
A statistical test of the null hypothesis of no change in each variable will be done using the Wilcoxon signed-ranks procedure.
Measurements of the two variables at additional time points will be analyzed in a descriptive fashion using tables and plots.
|
Up to 4 weeks post-treatment
|
Responses to veliparib in combination with carboplatin and paclitaxel
Time Frame: Up to 4 weeks post-treatment
|
Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.
|
Up to 4 weeks post-treatment
|
Time to progression (TTP)
Time Frame: Time from start of treatment to time of progression, assessed up to 4 weeks post-treatment
|
Progression will be evaluated in this study using the new international criteria proposed by RECIST.
TTP will be displayed for all patients and for patients who have responded; no formal statistical analysis is planned.
|
Time from start of treatment to time of progression, assessed up to 4 weeks post-treatment
|
Toxicities as assessed by CTCAE v.4.0
Time Frame: From the time of their first treatment with veliparib to up to 4 weeks post-treatment
|
Toxicities will be defined as regimen-related if they are possibly, probably or definitely related to treatment.
The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level.
Serious (≥ Grade 3) toxicities will be described on a patient-by-patient basis and will include any relevant baseline data.
|
From the time of their first treatment with veliparib to up to 4 weeks post-treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suresh Ramalingam, University of Pittsburgh Cancer Institute (UPCI)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Breast Diseases
- Genetic Diseases, Inborn
- Neoplastic Syndromes, Hereditary
- Ovarian Neoplasms
- Breast Neoplasms
- Hereditary Breast and Ovarian Cancer Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Poly(ADP-ribose) Polymerase Inhibitors
- Carboplatin
- Paclitaxel
- Albumin-Bound Paclitaxel
- Veliparib
Other Study ID Numbers
- NCI-2009-00258 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA099168 (U.S. NIH Grant/Contract)
- N01CM00038 (U.S. NIH Grant/Contract)
- P30CA047904 (U.S. NIH Grant/Contract)
- 7967 (CTEP)
- PCI-07-015
- CDR0000566233
- UPCI # 07-015 (Other Identifier: University of Pittsburgh Cancer Institute (UPCI))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Breast and Ovarian Cancer Syndrome
-
Institut Claudius RegaudUnknownHereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer SyndromeFrance
-
Barretos Cancer HospitalCompletedBRCA1 Hereditary Breast and Ovarian Cancer SyndromeBrazil
-
Abramson Cancer Center at Penn MedicineEnrolling by invitationOvarian Cancer | Genetic Predisposition to Disease | Breast Cancer Female | Hereditary Diseases | Gene Mutation-Related Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Cancer SyndromeUnited States
-
National Human Genome Research Institute (NHGRI)CompletedBreast CancerUnited States
-
University of Kansas Medical CenterRecruitingBreast Cancer | Hereditary Breast and Ovarian CancerUnited States
-
Georgetown UniversityVirginia Commonwealth University; Cornell UniversityCompletedHereditary Breast and Ovarian CancerUnited States
-
University of Southern CaliforniaStanford UniversityCompletedHereditary Breast and Ovarian CancerUnited States
-
UNICANCERInstitut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaboratorsRecruitingMutation | Hereditary Breast and Ovarian CancerFrance
-
Umeå UniversityKarolinska Institutet; Lund University; Göteborg UniversityEnrolling by invitationLynch Syndrome | Hereditary Breast and Ovarian Cancer Syndrome | Familial Breast Cancer | Hereditary Breast Cancer | Familial Colorectal CancerSweden
-
Georgetown UniversityCompletedHereditary Breast and Ovarian CancerUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States